retatrutide trial phase FDA Approval Status 2026: Everything We Know So Far Eli Lilly infiltrates anti-obesity market
Description
KFF Health News reported that doctors warn patients can run into serious problems if they increase their dosage too quickly or do not follow the recommended schedule
If approved, it would be the first needle-free GLP-1 RA on the market
Diabetes Obes Metab (2017) 19(9):120513
About 10% of participants on the highest dose discontinued treatment due to their adverse events, compared to 5% of those on placebo
